0001213900-26-057690
SEC filingQ1 results showed stable revenue at $19.4M with gross profit expansion to $11.6M from improved product mix, though operating loss widened to -$1.3M on elevated expenses and cash burn surged to -$12.6M from working capital shifts.
Vaso Corporation reported Q1 FY2026 results reflecting the ongoing impact of the 2025 VHC-IT business sale alongside shifts in its core operations. Revenue totaled $19.4 million, down 54.5% from $19.5 million in the prior-year quarter, as the divestiture reduced the revenue base while the company focused on remaining segments like network services and healthcare equipment sales for GE HealthCare.
Operating income deteriorated to a -$1.3 million loss, 9.2% worse than the prior -$1.2 million, as operating expenses outpaced gross profit gains. This pressured operating margin to -6.9%, underscoring expense discipline challenges in a lower-revenue environment post-divestiture. Net income narrowed to a -$887,000 loss, a 17.5% improvement from -$1.1 million, with diluted EPS unchanged at -$0.01, supported by non-operating factors not detailed in available metrics.
Cash flow from operations weakened sharply to -$12.6 million from -$566,000, signaling working capital volatility that amplified liquidity pressures despite stable headline losses. Management commentary affirms the company expects to generate sufficient cash flow from operations to meet obligations for at least the next twelve months, providing investor reassurance amid the burn.
Business drivers point to robust order intake, with deferred revenue increases principally due to new orders booked exceeding deliveries, bolstering backlog visibility. The network services segment's higher revenue and margin contributions exemplify adaptation post-VHC-IT, while healthcare capital equipment distribution remains core. Overall, these dynamics position Vaso to leverage mix improvements and backlog for recovery, though cash management remains key to sustaining liquidity as affirmed.